Mineralocorticoid receptor antagonists

Mineralocorticoid receptor antagonists has been studied in 196 papers since 2017: 3 trials and 101 observational studies in people, 3 in animals, 1 in cells, 84 reviews; 143 in the past year. The newest story, Nov 12, 2026: “Drug class tied to lower death risk on tafamidis in heart amyloidosis”.

Intervention

196 papers study it57 findingsUpdated

MeSH

78 new papers in 30 daysSee all 194 papers on mineralocorticoid receptor antagonists

At a glance

Independent labs found the same change in people. 23 independent labs in 14 countries.

“GLP-1/GIP dual receptor agonists, GLP-1RA, SGLT-2i, MRA, and ARNI were all associated with reduced risk of the composite outcome of worsening heart failure and cardiovascular death”
Comparative Evaluation of Current Therapeutic Agents for Heart Failure with Preserved Ejection Fraction (HFPEF)—A Systematic Review and Network Meta-analysisADA Scientific Sessions 2025 abstract2025doi:10.2337/db25-433-p

6 of its findings point the other way.

Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
  • 23 independent labs in 14 countries
  • 6 findings against
  • Funders: National Heart, Lung, and Blood Institute and others
  • 4 of 44 findings with company ties
  • Human trial3
  • Humans101
  • Animals3
  • Cells1
  • In silico1

Studies in people

1 study gave mineralocorticoid receptor antagonists to people and measured what changed.

What changedDesignPeopleSource

down: Lowers the risk of worsening heart failure and cardiovascular death

Review of trials52,934 people pooledIn patients with HFpEF, compared with non-usersADA Scientific Sessions 2025 abstract, Jun 13, 2025

What did studies of mineralocorticoid receptor antagonists find?

27

Studies of mineralocorticoid receptor antagonists measured 27 outcomes; the most studied are mortality (3 studies) and vascular fibrosis (2).

Mortality

no changein humans2downin humans1RR 0.8

3 studies
  1. Mineralocorticoid receptor antagonists were not clearly linked with mortality in humans (Tafamidis-treated transthyretin amyloid cardiomyopathy).

    HumansTafamidis-treated transthyretin amyloid cardiomyopathy

    Drug class tied to lower death risk on tafamidis in heart amyloidosis

    Archives of cardiovascular diseases
  2. Mineralocorticoid receptor antagonists were not clearly linked with mortality in humans (added to GDMT, patients younger than 80 years).

    Humansadded to GDMT, patients younger than 80 yearsn = 661

  3. Mineralocorticoid receptor antagonists decrease mortality in humans (compared with placebo) (RR 0.80; 95% CI 0.72-0.88).

    Reviewcompared with placebo

Vascular fibrosis

downin mice2

2 studies
  1. Mineralocorticoid receptor antagonists prevent vascular fibrosis in mice (ageing).

    Animalsageingaorta

  2. Mineralocorticoid receptor antagonists prevent vascular fibrosis in mice (long-term treatment in aged mice).

    Animalslong-term treatment in aged miceblood vessellong-termmales

Ischemic stroke

no changein humans1HR 1.39

1 study
  1. Mineralocorticoid receptor antagonists were not clearly linked with ischemic stroke in humans (HFpEF; compared with SGLT2 inhibitors after propensity score matching) (HR 1.39, 95% CI 0.95–2.04).

    HumansHFpEF; compared with SGLT2 inhibitors after propensity score matching1 year57.1% females

More on Ischemic stroke

Atrial fibrillation/flutter

no changein humans1HR 1.05

1 study
  1. Mineralocorticoid receptor antagonists were not clearly linked with atrial fibrillation/flutter in humans (HFpEF; compared with SGLT2 inhibitors after propensity score matching) (HR 1.05, 95% CI 0.92–1.19).

    HumansHFpEF; compared with SGLT2 inhibitors after propensity score matching1 year57.1% females

More on Atrial fibrillation/flutter

Prescription rate

downin humans1

1 study
  1. Mineralocorticoid receptor antagonists are linked with lower prescription rate in humans (prescription at discharge and over 12 months) (67.1% at discharge to 54.1% at 12 months).

    Humansprescription at discharge and over 12 months12 monthsn = 4,010

Oxidative stress and ROS signaling

downin human cells1−26%

1 study
  1. Mineralocorticoid receptor antagonists decrease oxidative stress and ROS signaling in human cells (coronary artery disease) (-25.7%).

    Cellscoronary artery diseaseperipheral blood mononuclear cell

More on Oxidative stress and ROS signaling

Aldosterone release

upin human cells1

1 study
  1. Mineralocorticoid receptor antagonists increase aldosterone release in human cells (coronary artery disease) (124.9 ± 13.9 pg/mL after blockade).

    Cellscoronary artery diseaseperipheral blood mononuclear cell

More on Aldosterone release

Cardiovascular and renal outcomes

upin humans1

1 study
  1. Mineralocorticoid receptor antagonists improve cardiovascular and renal outcomes in patients with HFpEF.

    Reviewin patients with HFpEF

Blood pressure

downin humans1

1 study
  1. Mineralocorticoid receptor antagonists decrease blood pressure in elderly individuals.

    Reviewin elderly individuals

Cognitive function

upin reviews1

1 study
  1. Mineralocorticoid receptor antagonists improve cognitive function in animal models with chronic aldosterone exposure.

    Reviewin animal models with chronic aldosterone exposure

Circulating antifibrotic biomarker signature

upin humans1

1 study
  1. Mineralocorticoid receptor antagonists induce circulating antifibrotic biomarker signature in humans (small trial in elderly male humans).

    Human trialsmall trial in elderly male humansshort-termmales

More on Circulating antifibrotic biomarker signature

All 27

What is mineralocorticoid receptor antagonists linked with?

16

Studies link mineralocorticoid receptor antagonists with 16 measures, most often mortality (6 studies), acute kidney injury (2) and major adverse cardiovascular events (2).

Mortality

downin humans5upin humans1HR 0.32–1.59

6 studies
  1. Mineralocorticoid receptor antagonists are associated with mortality in humans (HFpEF; compared with SGLT2 inhibitors after propensity score matching) (HR 1.59, 95% CI 1.18–2.14).

    HumansHFpEF; compared with SGLT2 inhibitors after propensity score matching1 year57.1% females

  2. Mineralocorticoid receptor antagonists are linked with a lower risk of mortality in humans after aortic valve replacement for severe aortic stenosis, propensity-matched (HR 0.74, 95% CI 0.63–0.86).

    Humansafter aortic valve replacement for severe aortic stenosis, propensity-matchedto month 60

  3. Mineralocorticoid receptor antagonists are linked with a lower risk of mortality in humans (HR 0.991, p=0.04).

    Humanscumulative exposure, after adjustment for bilirubin, NT-proBNP, left ventricle ejection fraction, LVAD type, HF etiology and atrial fibrillationcumulative MRA dose

  4. Mineralocorticoid receptor antagonists are associated with mortality in humans (HFrEF; multivariate analysis) (HR 0.41, 95% CI 0.23–0.74).

    HumansHFrEF; multivariate analysis12 months23% femalesn = 810

  5. Mineralocorticoid receptor antagonists are linked with a lower risk of mortality in humans (added to GDMT at discharge versus GDMT without MRA, adjusted for discharge parameters) (HR 0.32 (95% CI 0.11-0.99)).

    Humansadded to GDMT at discharge versus GDMT without MRA, adjusted for discharge parametersn = 224

  6. Mineralocorticoid receptor antagonists lower the risk of mortality in humans (heart failure).

    Reviewheart failure

Acute kidney injury

upin humans2HR 1.2

2 studies
  1. Mineralocorticoid receptor antagonists are associated with acute kidney injury in humans (HFpEF; compared with SGLT2 inhibitors after propensity score matching) (HR 1.20, 95% CI 1.00–1.44; P=0.046).

    HumansHFpEF; compared with SGLT2 inhibitors after propensity score matching1 year57.1% females

  2. Mineralocorticoid receptor antagonists are associated with acute kidney injury in patients with transthyretin cardiac amyloidosis receiving tafamidis.

    Humansin patients with transthyretin cardiac amyloidosis receiving tafamidisone and five years

More on Acute kidney injury

Major adverse cardiovascular events

upin humans1downin humans1HR 0.75–1.27

2 studies
  1. Mineralocorticoid receptor antagonists are associated with major adverse cardiovascular events in humans (HFpEF; compared with SGLT2 inhibitors after propensity score matching) (HR 1.27, 95% CI 1.05–1.53).

    HumansHFpEF; compared with SGLT2 inhibitors after propensity score matching1 year57.1% females

  2. Mineralocorticoid receptor antagonists are associated with major adverse cardiovascular events in humans (Hypertension with low renin; therapy initiated after renin measurement) (HR 0.75, 95% CI 0.60–0.92).

    HumansHypertension with low renin; therapy initiated after renin measurement

Atrial fibrillation

upin humans1downin humans1RR 0.62

2 studies
  1. Mineralocorticoid receptor antagonists are associated with atrial fibrillation in humans (Tafamidis-treated transthyretin amyloid cardiomyopathy).

    HumansTafamidis-treated transthyretin amyloid cardiomyopathy

    Drug class tied to lower death risk on tafamidis in heart amyloidosis

    Archives of cardiovascular diseases
  2. Mineralocorticoid receptor antagonists lower the risk of atrial fibrillation in humans (heart failure with reduced ejection fraction) (RR 0.62, 95% CI 0.43-0.90).

    Reviewheart failure with reduced ejection fraction

More on Atrial fibrillation

Cardiovascular death or first heart failure hospitalization

downin humans1

1 study
  1. Mineralocorticoid receptor antagonists are associated with cardiovascular death or first heart failure hospitalization in humans (HFmrEF/HFpEF; LVEF > 40%) (iHR 0.89, 95% CI 0.81–0.98).

    ReviewHFmrEF/HFpEF; LVEF > 40%

Heart failure exacerbation

upin humans1HR 1.16

1 study
  1. Mineralocorticoid receptor antagonists are associated with heart failure exacerbation in humans (HFpEF; compared with SGLT2 inhibitors after propensity score matching) (HR 1.16, 95% CI 1.05–1.28).

    HumansHFpEF; compared with SGLT2 inhibitors after propensity score matching1 year57.1% females

More on Heart failure exacerbation

Heart failure hospitalisation or cardiovascular mortality

upin humans1

1 study
  1. Mineralocorticoid receptor antagonists are linked with a higher risk of heart failure hospitalisation or cardiovascular mortality in humans after surgical or transcatheter aortic valve replacement, weighted Cox model.

    Humansafter surgical or transcatheter aortic valve replacement, weighted Cox model

    Three heart drug classes linked to lower risk after valve replacement

    ESC Congress 2026 abstract

Cancer therapy-related cardiac dysfunction

downin humans1OR 0.06

1 study
  1. Mineralocorticoid receptor antagonists lower the risk of cancer therapy-related cardiac dysfunction in humans (Receiving anthracycline- and/or anti-HER2–based chemotherapy; incident LVEF <50%) (OR 0.06, 95% CI 0.01–0.44).

    ReviewReceiving anthracycline- and/or anti-HER2–based chemotherapy; incident LVEF <50%heart

More on Cancer therapy-related cardiac dysfunction

Major adverse cardiovascular events

downin humans1RR 0.82

1 study
  1. Mineralocorticoid receptor antagonists lower the risk of major adverse cardiovascular events in humans (compared with placebo in hypertensive population) (RR 0.82; 95% CI 0.75-0.90).

    Reviewcompared with placebo in hypertensive population

More on Major adverse cardiovascular events

Hyperkalemia

upin reviews1

1 study
  1. Mineralocorticoid receptor antagonists raise the risk of hyperkalemia.

    Review

More on Hyperkalemia

Worsening heart failure and cardiovascular death

downin humans1

1 study
  1. Mineralocorticoid receptor antagonists lower the risk of worsening heart failure and cardiovascular death in patients with HFpEF, compared with non-users.

    Human trialin patients with HFpEF, compared with non-users

All 16

What acts on mineralocorticoid receptor antagonists?

2

Studies name 2 things that act on mineralocorticoid receptor antagonists: guideline era and major neurocognitive disorders.

Guideline era

upin humans1

1 study
  1. Guideline era is linked with higher mineralocorticoid receptor antagonists in humans across guideline eras.

    Humansacross guideline eras

Major neurocognitive disorders

downin humans1

1 study
  1. Major neurocognitive disorders are linked with lower mineralocorticoid receptor antagonists in individuals diagnosed with heart failure.

    Humansin individuals diagnosed with heart failure

More on Major neurocognitive disorders

Latest

Dec 2025: 1Jan 2026: 15Feb 2026: 6Mar 2026: 20Apr 2026: 3May 2026: 2Jun 2026: 4Jul 2026: 4Aug 2026: 2Sep 2026: 6Oct 2026: 58Nov 2026: 20141 papers in 12 months
Archives of Cardiovascular Diseases

Drug class tied to lower death risk on tafamidis in heart amyloidosis

Sodium-glucose cotransporter 2 inhibitors were linked to lower relative death rates versus nonuse, with hazard ratios of 0.56 at one year and 0.62 at five years.Sodium-glucose cotransporter 2 inhibitors were linked to lower relative death rates versus nonuse, with hazard ratios of 0.56 at one year and 0.62 at five years.

Cohort · 5,683 peopleInterventions

See all 194 papers on mineralocorticoid receptor antagonists